Reuters logo
3 years ago
BRIEF-GSK receives positive EMA opinion for melanoma drug Mekinist
April 25, 2014 / 2:51 PM / 3 years ago

BRIEF-GSK receives positive EMA opinion for melanoma drug Mekinist

April 25 (Reuters) - Glaxosmithkline Plc

* GSK receives positive CHMP opinion for Mekinist (Trametinib) in metastatic melanoma with a braf v600 mutation

* A final decision by EC is anticipated during Q2 of 2014

* CHMP recommendation based on randomised open label phase III study in 322 patients For the full story, click on Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below